Bristol Myers Squibb®

2026-2027

PHARMACEUTICAL INDUSTRY

FELLOWSHIP PROGRAM

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships

Letter From Senior Leadership

Dear Prospective Fellow,

On behalf of Bristol Myers Squibb (BMS) and the Ernest Mario School of Pharmacy, we would like to thank you for your interest in the Post-Doctoral Pharmaceutical Industry Fellowship Program. The pharmaceutical industry provides many exciting and dynamic opportunities, and the same is true at BMS in particular.

BMS truly differentiates itself by combining the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company. We never give up in our search for the next innovation that could mean new hope for patients who are urgently seeking new treatment options today. Constantly pushing the boundaries of scientific excellence, our medicines help millions of people in their fight against serious diseases. Focused on addressing areas of significant unmet medical need, we have exciting development programs in areas such as oncology, hematology, immunology, neuroscience, and cardiovascular diseases.

We recognize the importance of social responsibility and the innovative medicines we create. Our belief that "the priceless ingredient of every product is the integrity of its maker," shines through in how we hold ourselves to the highest standard of integrity. We are not only committed to making a difference in the lives of patients, but also in the global communities where we operate.

BMS places an equal commitment to the development of the individuals who work with us. To meet our mission of helping patients prevail over serious diseases, we are committed to developing a workforce that is diverse, inclusive and representative of the communities in which we operate. We want employees to bring their authentic selves to work and to use their perspectives to contribute in a unique and meaningful way to our mission. We champion these efforts at the highest levels of our organization to ensure our people are engaged and empowered.

Over the past 30 years, we have been creating a best-in-class fellowship program devoted to preparing unique and highly motivated individuals, like yourself, for a rewarding and successful career in our industry.

On behalf of everyone at BMS, we invite you to strongly consider joining our community of people working together to transform the lives of patients through one of the fellowships we offer with Rutgers, Ernest Mario School of Pharmacy. We wish you the best of luck during the recruitment process.

Sincerely,
Chris Boerner, Ph.D
Board Chair and Chief Executive Officer

Table of Contents

About Bristol Myers Squibb

Our Mission

To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Our Commitment

To our patients and customers, employees, global communities, shareholders, environment and other stakeholders, we promise to act on our belief that the priceless ingredient of every product is the integrity of its maker. We operate with effective governance and high standards of ethical behavior. We seek transparency and dialogue with our stakeholders to improve our understanding of their needs. We take our commitment to economic, social and environmental sustainability seriously, and extend this expectation to our partners and suppliers. As a responsible corporate citizen, we seek to actively improve the health of the communities where we live, work and serve. Around the globe, we promote health equity and seek to promote the health outcomes of populations disproportionately affected by serious disease. We believe our diverse and inclusive culture supports better outcomes for all patients and we seek diversity in all aspects of our business.

Our Biopharma Success

At Bristol Myers Squibb, we uniquely combine the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers' needs, giving maximum priority to accelerating pipeline development, delivering sales growth, and continuing to manage costs. In recent years, we have outperformed most mega pharma companies, diversified companies, and pure biotech companies, having delivered 11 new medicines since 2019, and have a growing registrational portfolio. We are a BioPharma leader with a commitment to patients with serious disease, focused on finding innovative medicines to address unmet medical needs. Having transformed Bristol Myers Squibb into a benchmark BioPharma company, we now stand on the frontier of new possibilities with a commitment to making a meaningful difference in the lives of our patients. Continuous innovation is critical to our BioPharma strategy and is enhanced by our diverse workforce and inclusive culture. Over the years, Bristol Myers Squibb and its employees have received numerous distinguished awards and recognitions. Furthermore, we have the honor of continuing a legacy as one of the 100 Best Corporate Citizens, maintaining a perfect score on the Corporate Equality Index, and having been recently named one of the World's Most Admired Companies.

Marketed Products & Innovative Pipeline

Bristol Myers Squibb focuses on discovering and developing innovative medicines that address serious diseases in areas of significant unmet medical need. We concentrate our research efforts in the following core therapeutic areas: Oncology, Hematology, Immunology, Cardiovascular, and Neuroscience.

150+
PROJECTS IN CLINICAL DEVELOPMENT

841M
PATIENTS REACHED THROUGH ACCESS & EDUCATION PROGRAMS

11.2B
IN RESEARCH & DEVELOPEMENT SPEND

50+ **INVESTIGATIONAL THERAPIES**

SEE OUR FULL PIPELINE HERE

Cutting edge technologies & discovery platforms
- Cell & gene therapy
- Protein homeostasis
- Biologics
- Small molecules
- Chemistry

Therapeutic areas with unmet needs
- Oncology
- Hematology
- Cardiovascular
- Immunology
- Fibrotic diseases
- Neuroscience

IMMUNOLOGY & NEUROSCIENCE

ORENCIA® (abatacept)

SOTYKTU™ (deucravacitinib) 6 mg tablets

ZEPOSIA® (ozanimod) | 0.92 mg capsules

COBENFY™ (xanomeline and trospium chloride) capsules
50mg/20mg, 100mg/20mg, 125mg/30mg

CARDIOVASCULAR

Eliquis® (apixaban) tablets 5mg 2.5mg

CAMZYOS™ (mavacamten) capsules

HEMATOLOGY

Reblozyl® (luspatercept-aamt) for injection 25mg • 75mg

SPRYCEL® dasatinib 100 mg tablets

ONUREG® (azacitidine) tablets 300mg • 200mg

INREBIC® (fedratinib) capsules 100mg

Empliciti® (elotuzumab)

IDHIFA® (enasidenib) tablets 100mg • 50mg

ONCOLOGY

KRAZATI® (adagrasib) | 200 mg TABLETS

OPDIVO® (nivolumab)

YERVOY™ (ipilimumab)

AUGTYRO™ (repotrectinib) 40 mg capsules

Opdualag™ (nivolumab and relatlimab-rmbw) Injection for intravenous use | 480 mg/160 mg

OPDIVO Qvantig™ nivolumab + hyaluronidase-nvhy SUBCUTANEOUS INJECTION

CELL THERAPY

Breyanzi® (lisocabtagene maraleucel) SUSPENSION FOR IV INFUSION

Abecma® (idecabtagene vicleucel) SUSPENSION FOR IV INFUSION

BMS Fellowship, Primary Campus Location

Princeton Pike (PPK)

Lawrenceville, NJ

Post-Doctoral Program Governance

Executive Steering Committee

Melissa Harris, PharmD
Senior Vice President,
Regional Clinical Operations

Executive Sponsor

Priya Darouian, PharmD
Senior Director, Customer Experience Strategy,
Medical Engagement Excellence, MedEx

Steering Committee Lead

Thomas Lehman, PharmD
Executive Director, WW Medical
Rheumatology

Steering Committee Co-Lead

Steering Committee Members

Cathy Merrill, PharmD
Senior Director, Medical
Evidence Generation

Matt Lupo, MCIS
Executive Director, US
Commercial Regulatory Affairs

Ijeoma Oyetunde, PharmD
Senior Director, WW
Medical Oncology Product
Design and Delivery Lead

Kim Tran, PharmD
Vice President, US Field
Medical Oncology

Victoria Berger, PharmD
Senior Clinical Scientist,
Immunology & Fibrosis
Clinical Develpoment

Peter Fendt, PharmD
Director, Business Insights
and Analytics

Austin Bock, PharmD
Associate Director, WW
Medical Cardiovascular,
Mavacamten Medical
Communications

Second-Year Co-Chief Fellows

Vaidehi Patel, PharmD, MBA, RPh

Second-Year Fellow

Global Regulatory Strategy

Sydney Ross, PharmD

Second-Year Fellow

US Field Medical Neuroscience and Medical Evidence Generation

Sharmaine Cubelo, PharmD

Second-Year Fellow

WW & US Oncology Medical Strategy

Bristol Myers Squibb®

2026-2027

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships

Bristol Myers Squibb®

COMMERCIAL

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships

COMMERCIAL | TWO-YEAR FELLOWSHIP | OFFERED 2026-2028

US & WW CAR-T Marketing and Commercial

This newly created two-year commercial fellowship provides a unique opportunity to work in a fast-paced environment, emulating the speed of a biotech while existing in the structured lattice of a large pharma company. The Fellow will be involved in efforts that shape product strategies, drive the US CAR-T business, and identify commercialization opportunities on clinical stage and in-line CAR-T products. The Fellow will spend their first year as a member of the US CAR-T marketing team collaborating with the matrix and external partners to ensure successful and timely execution of the brand strategy. Their second year will be spent in the WW Commercial CAR-T organization identifying market opportunities and developing commercial strategies that maximize US entry for future launches. The individual selected for this fellowship will have the chance to leverage their clinical background as they deliver on marketing strategies and assess the commercial opportunities of future CAR-T products. During this program, the Fellow will:

US CAR-T MARKETING

- Drive execution of the Health Care Provider (HCP) tactical plan
- Regularly evaluate competitive landscape and marketplace dynamics
- Navigate internal review processes to ensure timely and accurate preparation of tactical projects
- Manage agency/vendor partners to develop promotional materials and tactics
- Contribute tactical and strategic recommendations based on key internal and external medical and clinical updates from congresses, publications, etc
- Interact with customer-facing teams to mine customer insights, leading to the development of professional promotional strategy and materials

WW CAR-T COMMERCIAL

- Identify key value drivers and develop target product profiles based on understanding of current and potential market future trends
- Collaborate with key matrix team members to deliver robust market opportunity assessments that include a comprehensive review of the external competitive environment, external insights gathered from market research and discussions, market access considerations and revenue projections

US Market Access



Lauren Hunter, PharmD, MBA, RPh

Second-Year Fellow
Butler University College of Pharmacy & Health Sciences

Tazche Turner, PharmD

First-Year Fellow
University of North Carolina, Eshelman School of Pharmacy

This two-year fellowship offers the opportunity to join a rapidly-evolving access organization that leads in the industry to ensure patient and provider access to therapy. Within the fellowship program, the Fellow will have the opportunity to gain experience working in multiple components of the organization, with an emphasis in Hematology and Oncology. Through three rotational opportunities, the Fellow will build core foundational marketing skills, develop a comprehensive understanding of drug pricing, payer-provider reimbursement, and patient affordability. Additionally, the Fellow will gain exposure to many unique experiences and gain valuable insight into tactics and cross-matrix initiatives used to ensure patient access to quality care.

The fellowship is structured in flexible rotations within the core US market access teams which includes Patient Access Support Services, Pricing & Contracting, and Access Strategy. During this program, the Fellow will:

PATIENT ACCESS SUPPORT SERVICES

- Evaluate the evolving healthcare landscape to assess the implications for provider reimbursement and patient affordability
- Create materials, including both traditional and digital content, to communicate the proper billing and coding for infusible products to support launch and label updates

PRICING & CONTRACTING

- Understand challenges and business drivers across multiple channels including Payers, Integrated Delivery Networks, Group Purchasing Organizations, and Pathway organizations
- Gain experience in economic modeling to shape pricing strategy for new and existing products based upon shifting marketplace pressures and dynamics

ACCESS STRATEGY

- Contribute to the brand payer strategy by evaluating payer management trends, emerging access influencers, and the evolving competitive landscape
- Interact with medical strategy, health economics and outcomes research, and market research to develop promotional materials that communicate the value of our products to managed care organizations

ADDITIONAL EXPERIENCES

- Engage in field rides with external stakeholders alongside Access and Reimbursement Managers, Health Systems Liaisons, and Account Executives
- Participate in potential opportunities with US market access matrix teams such as US Federal Policy, US Oncology Brand Marketing, and Global Market Access

Bristol Myers Squibb®

CLINICAL DEVELOPMENT

PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships



Global Drug Development



Leah White, PharmD
Second-Year Fellow
UNC Eshelman School of Pharmacy

Mirna Kalayjian, PharmD
Second-Year Fellow
University of California, San Francisco School of Pharmacy

Justine Del Prado, PharmD
First-Year Fellow
Rutgers University Ernest Mario School of Pharmacy

The Global Drug Development (GDD) organization is responsible for developing new medicines for the treatment of various diseases worldwide. Fellows within GDD function as Associate Clinical Scientists (CS) and will focus on the science and strategy of drug development. The Fellows will learn various aspects of global clinical studies (Phases I-III) including study development and start-up, conduct, and closure activities.

GLOBAL DRUG DEVELOPMENT FELLOWSHIP OBJECTIVES:

- Understand the key foundations of clinical trial development and how they relate to the overall drug development process (i.e. study design, selecting study endpoints, randomization/stratification, control, blinding, selection of population, and study assessments).
- Become a proficient CS and effective cross-functional study team contributor throughout the clinical trial process by learning to write and review study protocols and protocol amendments, informed consent forms, patient narratives, clinical study reports (CSR), Investigator Brochures (IB), Investigational New Drug (IND) safety updates, Development Safety Update Report (DSUR), and other regulatory submission documents.
- Working closely with the CS's, CTP's (Clinical Trial Physician), and study team in making study-specific recommendations, providing clinical research expertise, presenting protocol specific topics, responding to health authority requests, engaging with investigator sites' personnel to address inquiries and resolve issues, and supporting the team at various therapeutic area conferences.
- Support the study team in comprehensive clinical data review and analysis via available data review tools such as patient profiles, data review reports, and data listings.
- Partner with Clinical Operations, Data Management, Statistics, Drug Safety, Regulatory, Clinical Pharmacology, Medical and Commercial teams to support the scientific aspects of clinical development.

The Global Drug Development fellowship is a 2-year program primarily focused on developing new therapies in solid tumor oncology, hematology, cellular therapy, cardiovascular, neuroscience, and immunology. This opportunity will allow the Fellow to work on novel and innovative therapies for the treatment of patients with serious diseases. Bristol Myers Squibb is at the forefront of drug research with a broad and robust pipeline. This fellowship opportunity will allow the Fellows to work on novel and innovative therapies that address the unmet medical needs of patients with serious diseases.

Cellular Therapy GDD: Recruiting 1 Fellow

Hematology GDD: Recruiting 1 Fellow

Oncology GDD: Recruiting 1 Fellow

Bristol Myers Squibb®

MEDICAL

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships

WW Oncology Medical Education & Communications

Sirisha Neti, PharmD

Second-Year Fellow
Rutgers University Ernest Mario School of Pharmacy

Smruti Rajpara, PharmD

First-Year Fellow
Rutgers University Ernest Mario School of Pharmacy

This two-year fellowship provides a structured and comprehensive learning experience focused on oncology medical communications and strategy within our global medical organization. The fellowship includes rotational experiences in key areas of our WW medical organization, starting with WW Oncology Medical Education, followed by WW Oncology Medical Communications, with the possibility of extension projects based on the Fellow's interests in areas such as US medical strategy, promotional review, etc. The program is designed to equip the Fellow with a deep understanding of strategic planning and execution across both marketed products and pipeline assets.

Key responsibilities will be to:

- Support medical teams in the development and implementation of strategic initiatives
- Contribute to the execution of activities that enable successful product launches
- Assist in the design and delivery of healthcare provider (HCP) education programs
- Promote the safe and appropriate use of our medicines through evidence-based communication

MEDICAL EDUCATION

- Understand what Independent Medical Education (IME) is and the role it plays in the organization
- Understand IME medical strategy and functional plan
- Develop proficiency in medical education grant proposal review, know what a robust grant consists of, and understand the learning science of Adult Learning Principles
- Author a request for education (RFE) and lead it through the execution process from start to finish
- Evaluate BMS-supported medical education activities assessing medical accuracy, fair-balance, and alignment to approve grant proposals
- Analyze outcomes data from BMS-supported medical education activities and communicate behavioral changes, competence/knowledge gains, learner questions and remaining education gaps to the medical matrix teams
- Interface with medical education communication companies to understand provider capabilities and assess outcomes of activities

MEDICAL COMMUNICATIONS

- Function as a Medical Communications lead to enable the healthcare community to advance the science, accelerate access, shape medical practice, and drive appropriate adoption of Bristol Myers Squibb medicines
- Manage across a global matrix organization (e.g., Legal, Medical, Clinical Development, Translational) to drive quality planning and timely delivery of strategically aligned medical communications, including publications, congress presentations, and scientific content (e.g., Q&As and reactive slide decks)
- Partner closely with the medical information contact center in responding to unsolicited requests from HCPs, payers, and patients
- Understand the communication needs across the therapeutic area and disease area that incorporate and align with enterprise-level strategies for the development and execution of functionally integrated medical communication plans, with application and pull-through to Scientific Communication Platforms and Scientific Narratives

MEDICAL | TWO-YEAR FELLOWSHIP | OFFERED 2026-2028

US Cardiovascular Medical Strategy & Field Medical Sciences

Mike Zatkos, PharmD, RPh

Second-Year Fellow
University of Pittsburgh
School of Pharmacy

Emily Tran, PharmD

First-Year Fellow
University of Arizona R.
Ken Coit College of Pharmacy

This two-year fellowship provides a unique opportunity to develop expertise in strategic in-house medical affairs and field medical activities. The Fellow will acquire cardiovascular disease state knowledge and master the BMS cardiovascular product portfolio. Additionally, the Fellow will work on high priority projects and initiatives aligned with the Medical Plan to support impactful HCP interactions. The Fellow will develop leadership and communication skills through collaboration across the US Medical matrix teams and other key partners. Key activities and learnings will include:

MEDICAL STRATEGY

- Participate in the US Medical matrix team to support strategic planning based on the unmet medical needs from the perspectives of patients, providers, and payers
- Support the execution of the Medical Strategy tactical plan by working across matrix teams (Marketing, Field Medical, Medical Communications, Advocacy, Clinical Development, Legal and Regulatory) as well as with alliance partners
- Collaborate with cross-functional medical team members to deliver on key medical initiatives, including advisory boards, proactive messaging, reactive medical communication, and publication strategy
- Support development of medical training materials for sales representatives and deliver medical presentations at sales training sessions
- Contribute towards congress strategy and lead the execution of National Congress planning activities as part of the CV Medical Plan

FIELD MEDICAL SCIENCES

- Complete MSL trainings and certification process for the CV profile
- Engage thought leaders in scientific discussions during field-based activities with CV MSLs
- Assess/identify gaps in MSL resources and collaborate with medical strategy on the development of MSL scientific resources and trainings
- Collaborate with the Field Medical Leadership Team to support development and implementation of field medical priorities
- Contribute to scientific congress Field Medical initiatives and planning
- Develop an understanding of clinical trial site maintenance and the MSL educational role

US & Worldwide Medical Strategy: CAR-T & Autoimmunity



Alex Kayal, PharmD, RPh

Second-Year Fellow
Rutgers University Ernest Mario School of Pharmacy

Satchell Medé Pacheco, PharmD

First-Year Fellow
Florida A&M Univeristy College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health

This two-year fellowship provides a unique opportunity to work in two of the most exciting and competitive areas of research and pharmaceutical development today: CAR-T cell therapies and Autoimmune Disease. Individuals participating in this fellowship will gain a broad understanding of Medical Affairs through both participatory and leadership experiences from the perspective of both the US and Worldwide Medical Strategy Teams. During the fellowship, the Fellow is expected to experience several important market events including pre and post-launch activities in both Rheumatology and Hematology; and several phase 2/phase 3 study read outs. Graduates of this fellowship have gone on to lead successful careers in various aspects of Medical Affairs including Medical Strategy, Medical Communications, Clinical Development, Medical Science Liaison, Medical Information, and Independent Medical Education.

US MEDICAL STRATEGY: CAR-T CELL THERAPY

- Participate in strategic planning with collaborators from across the US & Worldwide Medical Matrix Team members
- Lead medical projects in partnership with the broader medical matrix team (Field Medical, Medical Communications, Medical Evidence Generation, Medical Education, Sales, Marketing, Outcomes Research, Promotional Review, Legal, and Pharmacovigilance)
- Lead and participate in key aspects of medical affairs including data generation, content development, training, insight reporting, advisory boards, and congress planning
- Participate in projects unique to CAR-T cell therapy including efforts to support ecosystem evolution that enable patient access to CAR-T cell therapies in various clinical practice settings
- Experience applications of CAR-T cell therapy across different therapeutic areas including Hematologic Malignancy as well as Autoimmune Disease

WORLDWIDE MEDICAL STRATEGY: RHEUMATOLOGY

- Lead development and execution of the Global Medical Plan in partnership with key international market teams (eg, US, EU, Asia-Pacific), Clinical Development, & Commercial
- Prepare for a commercial launch and several Phase 2/3 data releases for deucravacitinib (a selective TYK2 inhibitor) in Rheumatology
- Engage International Key Opinion Leaders via advisory boards, steering committees, and international conferences to inform and elevate BMS strategy
- Identify educational needs among Rheumatologists and execute plans to fulfill them; eg, disease education, pathway materials, conference symposia, review articles
- Develop integrated data generation plans and review/approve investigator sponsored research proposals to inform appropriate use of BMS medicines and fulfill unmet medical need

WW & US Oncology Medical Strategy



Sharmaine Cubelo, PharmD

Second-Year Fellow
Temple University School of Pharmacy

Mia Como, PharmD

First-Year Fellow
University of Pittsburgh School of Pharmacy

Medical Strategy is where scientific and clinical knowledge meet strategic application. This two-year fellowship provides a unique opportunity to support the development and execution of Worldwide and US Oncology Medical Strategy and other medical activities. During the first year in Worldwide Medical Oncology, the Fellow will focus on developing the global strategy for new indications in a wide array of tumor types through collaborative efforts with BMS regional offices around the world. During the second year in US Medical Oncology, the Fellow will focus on developing and executing the US strategy for the success and continued support of a wide range of indications through medical engagements, conferences, and launches. Throughout these 2 years, the Fellow will gain exposure to various stakeholders and develop leadership skills by supporting and leading medical initiatives in collaboration with the Worldwide and US cross functional matrix teams (e.g., Clinical Development, Clinical Operations, Regulatory, Medical Communications, Field Medical, Commercial, HEOR, Competitive Intelligence, Access and more). Additionally, the Fellow will have opportunities to collaborate closely with the patient advocacy team. This includes partnering to present and execute patient advocacy advisory boards, attending patient advocacy meetings at congresses, and developing various patient-related tactics. This will provide the Fellow with a deep understanding of how our work directly impacts patients' lives.

WORLDWIDE MEDICAL STRATEGY

- Gain experience in the development of a strategically-aligned Global Medical Plan based upon unmet medical need by collaborating with a cross functional, multi-regional (i.e., US, EU, Asia-Pacific) Worldwide Medical matrix team
- Engage with external Thought Leaders in an effort to exchange and gather scientific and clinical knowledge through investigator meetings, advisory boards, Thought Leader Engagements (TLEs), publication planning, and congresses
- Lead the execution of medical deliverables that are closely aligned with the strategic Global Medical Plan, including National and International Congress planning for activities such as advisory boards, symposia, and TLEs
- Collaborate with BMS country-specific medical colleagues to collect field insights that will support strategic planning and tactical execution
- Actively participate in the review and approval process of Investigator Sponsored Research proposals that are aligned with the data generation plan detailed in the Global Medical Plan

US MEDICAL STRATEGY

- Participate in key medical activities such as medical advisory boards, Field Medical resources and trainings, Congress planning (e.g., ASCO, ASCO GI), reactive content, and aid in the development of the communication strategy, including publications
- Collaborate with US Medical matrix teams (e.g., Field Medical, Evidence Generation, Patient Advocacy, Medical Education, and Congress Management) to support planning and delivery of medical objectives based on unmet medical needs
- Collaborate and communicate with US Commercialization & Access organizations to integrate medical perspectives into the commercialization process and ensure appropriate alignment between commercial and medical plans
- Engage with external thought leaders and scientific experts to assess unmet medical needs to develop appropriate medical strategies

US Field Medical Neuroscience and Medical Evidence Generation (MEG)

Sydney Ross, PharmD

Second-Year Fellow
University of Iowa College of Pharmacy

Mitchel Haykal, PharmD

First-Year Fellow
Binghamton University School of Pharmacy and Pharmaceutical Sciences

The US Field Medical Neuroscience and Medical Evidence Generation (MEG) position is a two-year fellowship that will provide a unique opportunity to gain expertise in multiple dimensions of the medical affairs function in the neuroscience space. During their first year, the fellow will join the US Field Medical Neuroscience team and participate in key projects, critical to the success of new product/indication launches and currently approved products across assets within the Neuroscience organization. The fellow will gain an appreciation for core Field Medical competencies spanning field training, resource creation, operations, and thought leader (TL)/ investigator engagement. The fellow will have the opportunity to learn the intricacies of the MSL role via training, field rides, and scientific congress attendance. In their second year, the fellow will join the MEG team and contribute to the development and implementation of the Integrated Evidence Plan (IEP) and interact with the different modalities of evidence generation (investigator-sponsored studies, interventional and noninterventional company-sponsored trials, collaborative research, and exploratory analysis among others). The fellow will focus on the science and strategy of MEG generated studies, learning various aspects of clinical studies (Phase IIIb/IV) including study design, initiation, maintenance, and closure activities.

US FIELD MEDICAL NEUROSCIENCE

- Serve as an integral part of the Field Medical Neuroscience Strategy and Operations team and key contributor for field medical planning, stakeholder communications, MSL training, and launch/life-cycle management projects
- Gain product and therapeutic expertise via MSL trainings, validations, and assessments in Neuroscience as foundational knowledge to apply to various projects and activities
- Collaborate with home office medical, medical learning, and field matrix teams to assist in the development of training initiatives and medical resources, including opportunity for stretch projects with these teams
- Contribute on innovative tactics and/or platforms to elevate MSL development and productivity in the field including resource launches, technology updates, and serving as point of contact for MSL troubleshooting
- Interact with external TLs throughout the fellowship year on field rides with MSLs and activities at scientific congresses. The Fellow will have the opportunity to accompany MSLs on field rides and virtual interactions to gain an understanding of diverse experiences with TLs and study investigators At congresses the fellow will experience the responsibilities of a MSL including presenting BMS data, competitive intelligence coverage, medical booth support, and gathering insights from thought leaders
- The fellow will collaborate across the cross-functional matrix team, including commercial, medical affairs, and other key stakeholders, to align on strategic priorities and drive cross-functional excellence in the field

MEDICAL EVIDENCE GENERATION (MEG)

- Support the development, tracking and maintenance of Integrated Evidence Plans (IEPs) that reflect asset strategy, market priorities and medical evidence generation support in partnership with the Global Medical Disease Team and cross-functional teams including Global Drug Development (GDD), Translational Development, Health Economics and Outcomes Research (HEOR), and others
- Co-develop Areas of Interest (AOI) based on key open data questions (ODQ) identified in the IEP with market input in collaboration with the Global Medical Disease Teams
- Assist with the scientific aspects of the ongoing Investigator-sponsored Research (ISR) book of work and interface with all key stakeholders across the matrix
- Conduct regular book of work reviews in partnership with GDO (Global Development Operations) with key medical and development stakeholders, under their remit. Identify studies at risk for failing to meet timelines and negotiated mitigation plans with key internal stakeholders and investigators
- Assist in the reviews of concepts through RFP (Request for Proposals) process, as appropriate, including providing context for ongoing book of work, area of interest development, and upcoming data read-outs
- On MAST studies: work closely with the CTL (Clinical Trial Lead) and study team in making study-specific recommendations, providing clinical research expertise, presenting protocol specific topics, responding to health authority requests, and supporting the team at various therapeutic area conferences
- On CRCs (Clinical Research Collaboration): lead protocol development and trial activation in close collaboration with external investigators to align with the IEP and BMS's strategic imperatives
- Support the study team in comprehensive clinical data review and analysis via available data review tools such as patient profiles, data review reports and data listings

MEDICAL | TWO-YEAR FELLOWSHIP | OFFERED 2026-2028

US Field Medical: Oncology & Hematology

Ryan Kendra, PharmD

Second-Year Fellow

Binghamton University School of Pharmacy and Pharmaceutical Sciences

This two-year fellowship provides an opportunity to develop an understanding of US Field Medical. The fellow will be afforded the opportunity to build a strong foundation through their exposure to both the BMS Medical Science Liason (MSL) team, as well as opportunities to collaborate cross-functionally as they support pre-launch activities. Throughout the course of this fellowship, the individual will not only acquire disease state knowledge but also master clinical data regarding Bristol Myers Squibb and competitor products. The fellow will be able to partner closely with the Home Office Medical (HOM) team, as well as collaborate within a cross-functional matrix (e.g., Legal/Regulatory, Medical, Clinical Development, and R&D) through leading Fellow-driven projects with demonstrable business impact.

US FIELD MEDICAL HEMATOLOGY

- Undergo product and therapeutic area expertise trainings to function as a field-ready member of the MSL team. The fellow will have the opportunity to collaborate with MSL's in their interactions with TLs and study investigators both in the field and at congresses
- Play a critical role in the collection and analysis of insights, Medical Account Planning, and tumor specific training to gain an understanding of the market and therapeutic landscape
- Work collaboratively with the Home Office Medical team to develop and present scientific trainings for the MSL team
- Work directly on headquarters–based field medical projects, and attend key Bristol Myers Squibb meetings (i.e., National Oncology Meetings, Medical Congresses, Continuing Medical Education, Medical Matrix collaboration, and Medical Science Liaison training)
- Participate in weekly Field Medical meetings (regional calls, journal clubs, and national meetings).
- Analyze key field metrics with FM Leadership Team and understand business impact

MEDICAL | TWO-YEAR FELLOWSHIP | OFFERED 2026-2028

US Hematology Medical Strategy

Timothy Jurasik, PharmD

Second-Year Fellow
Temple University School of Pharmacy

Justine Khalil, PharmD

First-Year Fellow
Rutgers University Ernest Mario School of Pharmacy

The two-year Medical Affairs fellowship is designed to provide broad exposure and opportunities to understand the various roles within the Hematology Medical Affairs organization. Throughout the fellowship, the Fellow will deepen their expertise in hematology by gaining a thorough understanding of disease states and mastering clinical data related to the Bristol Myers Squibb product portfolio as well as competitor data. The Fellow will learn various aspects of clinical research (company sponsored trials, investigator-initiated trials, cooperative group trials, and registries) while working collaboratively with medical disease teams and cross-functional partners.

US MEDICAL

- Gain a broad knowledge and understanding of assigned disease areas including, but not limited to: disease biology, currently available therapeutic options, agents in development, and unmet medical needs for specific patient segments
- Gain product-related expertise in each assigned disease area and engage in scientific and strategic discussions with key internal and external stakeholders
- Support the medical disease teams with content preparation and planning for medical congresses (e.g. ASCO, ASH) and other key external meetings, including advisory boards, scientific steering committee meetings, and thought leader engagements
- Collaborate with cross functional team members, including Medical Science Liaisons (MSLs), Scientific Communications, Scientific Education, Medical Information, and Learning & Development teams, to create and execute on medical tactical plans

WW Hematology Medical Communications and Medical Strategy

Elaine Marji, PharmD

Second-Year Fellow, Cardiovascular
University at Buffalo School of Pharmacy and Pharmaceutical Sciences

Devin John, PharmD

First-Year Fellow, Cardiovascular
St. John's University College of Pharmacy and Health Sciences



Mariam Mckee, PharmD

First-Year Fellow, Immunology
University of South Florida Taneja College of Pharmacy

This two-year fellowship provides an opportunity to work across the Medical Communications and Medical Strategy functions within the Worldwide Medical Oncology (hematology) organization. The Fellow will learn how to communicate key clinical and economic data across various channels to inform healthcare decision-making. Within this role, the Fellow will gain experience in the generation of strategic and prioritized scientific publications, content, and medical education for Health Care Providers (HCPs) and patients. In the first year, the Fellow will become adept in the planning and execution of scientific communication deliverables. In the second year, the fellow will gain a broader understanding of Medical Affairs through participation and leadership in experiences from the perspective of the Worldwide Medical Strategy team. This position encourages the cultivation of critical thinking and leadership skills through cross-functional collaboration with various internal and external stakeholders (e.g., Medical Strategy, Medical Information, Health Economics and Outcomes Research (HEOR), Field Medical, Clinical Development, Clinical Science, Field HEOR, Legal and third-party vendors). Key activities and learnings will include:

MEDICAL COMMUNICATIONS

SCIENTIFIC PUBLICATIONS

- In collaboration with WW & US Medical Strategy, external authors, and appropriate internal stakeholders, develop publications adhering to BMS publication standards including abstracts, congress presentations, and manuscripts focused on disease burden, unmet medical needs, and the clinical and economic value of BMS assets
- Lead the execution of publication plans and develop skills for managing stakeholders, both external and internal, in multiple functional areas to ensure strategic alignment of the publication plans

WW AND US SCIENTIFIC CONTENT

- Understand the unique information needs of HCPs and patients to ensure strategic and prioritized information delivery
- Collaborate with WW & US Medical Strategy, HEOR, medical field teams, and other stakeholders to ensure development of fair-balanced scientific narratives, platforms, and content with the highest degree of medical integrity, accuracy, and clinical relevance
- Lead content creation of medical communication deliverables including AMCP dossiers, NCCN/Clinical Pathways submissions, reactive slide decks, and FAQs for field medical.

MEDICAL EDUCATION

- Execute BMS-led satellite symposia at key international congresses (e.g. European Hematology Association [EHA])
- Evaluate unsolicited IME/CME medical education grant proposals for medical accuracy, fair balance, and alignment to overall asset/indication medical strategy
- Analyze outcomes data from BMS-led satellite symposia and BMS-supported IME/CME medical education activities and develop reports on metrics such as demographic reach, target audience, downloads, and impact on clinician learners

MEDICAL STRATEGY

- Participate in the Medical Matrix Team to support strategic planning based on the unmet medical needs from the perspectives of patients, providers, and payers
- Collaborate with cross-functional medical team members to deliver on key medical initiatives including advisory boards, proactive messaging, reactive medical communication, and publication strategy
- Engage with international Key Opinion Leaders to exchange and gather scientific and clinical knowledge through investigator meetings, advisory boards, Thought Leader Engagements (TLEs), publication planning, and congresses
- Contribute to the evaluation of investigator-initiated trial concepts and how each concept strategically relates to open research questions that have been prioritized within the department and disease team

Bristol Myers Squibb®

REGULATORY

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships

Global Regulatory Strategy

Vaidehi Patel, PharmD, MBA, RPh

Second-Year Fellow
Saint Josephs University, Philadelphia College of Pharmacy

Jessica Priya Saini, PharmD

First-Year Fellow
Fairleigh Dickinson University School of Pharmacy and Health Sciences

This two-year fellowship, in Global Regulatory Sciences, provides the opportunity to establish a broad understanding of Global Regulatory Strategy and its role in the drug development process. The Fellow will obtain direct experience and exposure to products at various stages of development and will learn important considerations for working with key regulatory agencies such as FDA and EMA. Optional rotation(s) to enhance the fellowship experience are offered based on Fellow interest and opportunities in other regulatory disciplines such as Precision Medicine, Commercial Regulatory Affairs, or Global Labeling. During this program, the Fellow will:

- Participate in the development of global regulatory strategies supporting development, approval, and maintenance of drugs and biologics
- Contribute to identification and assessment of regulatory risks and their mitigation
- Participate in planning and preparing for Health Authority (HA) interactions and assessing the impact of HA feedback on an asset's development plan
- Draft submission documents, including for INDs, NDA/BLAs, and expedited regulatory designation requests
- Conduct regulatory intelligence research to inform development program strategy and decision-making
- Manage responses to Health Authority queries
- Collaborate with matrix team members to identify solutions that meet regulatory requirements as well as commercial objectives
- Partner with Global Regulatory Policy team to evaluate evolving regulatory topics

US Commercial Regulatory Affairs: Advertising & Promotion

Roshan Rao, PharmD, RPh

First-Year Fellow
Rutgers University, Ernest Mario School of Pharmacy

The US Commercial Regulatory Affairs group at Bristol Myers Squibb provides strategic regulatory guidance within the company on the Food and Drug Administration (FDA) advertising and promotion regulations to support good business practices. The regulatory advice is provided to the marketing organization to ensure the highest level of ethics and integrity in the promotion of Bristol Myers Squibb products. The group collaborates with a variety of functions including Marketing, Medical Affairs, Legal, Global Labeling, Managed Markets, Global Regulatory, and Safety. The Fellow will be assigned to a primary therapeutic area.

Key activities and learnings will include:

- Gaining an understanding of and ensuring consistency between key federal regulations and Bristol Myers Squibb policies
- Analyzing the impact of FDA Office of Prescription Drug Promotion (OPDP) enforcement actions and assessing the regulatory implication to commercial activities
- Assisting in the regulatory review of proposed promotional materials and programs created by Marketing, Sales, or Corporate Affairs and submissions to OPDP
- Collaborating with matrix team members to advise on the development of marketing campaigns that meet regulatory requirements as well as commercial objectives

Bristol Myers Squibb®

BMS RESIDENCY

PHARMACEUTICAL INDUSTRY
FELLOWSHIP PROGRAM

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships

Bristol Myers Squibb Foundation: PGY2 PharmD/Public Health Residency

Jodi-Ann Haynes, PharmD

Resident
University of Maryland
School of Pharmacy

The Bristol Myers Squibb Foundation's (BMS Foundation) approach to improving global health is empowering local health systems through strategic investments in capacity building and health systems strengthening initiatives, improving access to healthcare, and promoting health equity worldwide. The program offered through the Rutgers Institute for Pharmaceutical Industry Fellowship Program and Ernest Mario School of Pharmacy, entails the Resident spending approximately six months in Sub-Saharan Africa with the Bristol Myers Squibb Foundation Adult Cancers program team to build pharmacology capacity and transfer skills to partner organizations. Activities may include:

- Training of pharmacy and other healthcare professionals in disease state management and pharmacotherapy
- Developing protocols and proposals incorporating the management of cancer in low to middle-income countries (LMICs)
- Assisting countries develop cancer surveillance programs and registries to collect data and develop treatment recommendations
- Exposure to project implementation and management on field sites
- Engaging community members and organizations through outreach to help improve health outcomes

The Resident will then complete the remainder of the program in Lawrence Township, New Jersey and New York City, developing a grant management and operations skill set through the Neuropsychiatry portfolio and/or other BMS Foundation initiatives (including our Adult Cancers portfolio in the United States, Brazil and India, and the Robert A. Winn Excellence in Clinical Trials Awards Program) that address access to healthcare. Activities may include:

- Supporting grant management activities to gain greater insight into health philanthropy within the pharmaceutical industry setting
- Researching issues for the development of grant program strategies
- Providing expert review and technical assistance for pharmacy -related issues
- Connecting project goals with policy and advocacy advancement
- Reviewing grantee reports and learning responsibilities as a grantmaker

As a Rutgers adjunct faculty through the Rutgers University Ernest Mario School of Pharmacy, there will be opportunities for the Resident to enhance their experience by collaborating with faculty through scholarship, publication, teaching and maintenance of clinical skills.

APPLICATION REQUIREMENTS:

Applicants can pre-schedule an interview at the ASHP Midyear Clinical Meeting through the Personnel Placement Service (PPS). Requirements include: PharmD from an ACPE-accredited institution, Completion of a PGY-1 residency or equivalent experience is strongly preferred, Curriculum vitae, Three letters of recommendation, Letter of intent addressing your interest in global/public health and long-term plans, and Candidates must be willing and able to relocate to sub–Saharan Africa for 6 months.

Bristol Myers Squibb®

CORPORATE AFFAIRS & POLICY

PHARMACEUTICAL INDUSTRY

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships



Policy & Patient Advocacy

Alexis Glenn, PharmD

Second-Year Fellow
University of Maryland School of Pharmacy

This industry leading fellowship provides opportunities to work with seasoned professionals within both US Policy & Government Affairs and Global Patient Outreach. The Fellow will gain experience working across a matrix team (commercial, clinical development, medical, HEOR, market access, communications and legal) to gather expert patient advocate insights, engage with relevant non-profit organizations, develop advocacy plans that optimize access to high quality medicines for patients and incorporate patient input into the drug development lifecycle continuum. During this time of continued reform and evolution of the U.S. healthcare system, the Fellow will develop a deep understanding of how healthcare policies are developed and implemented within the US, and how they impact patients, providers, payers, and the biopharmaceutical industry. The Fellow will interact and collaborate with stakeholders across Bristol Myers Squibb and gain experience working with patient advocacy organizations, professional societies, trade associations, policy stakeholders and other entities that contribute to the policymaking process and the overall changing healthcare landscape. Fellows will gain firsthand experience accompanying colleagues to Capitol Hill visits and attending policy focused conferences and programming to understand access and affordability issues that impact patients, while collaborating with external stakeholders to align on public policy.

U.S. POLICY & GOVERNMENT AFFAIRS

- Evaluate U.S. healthcare policy proposals and conduct thorough analyses to support the federal and state government affairs teams in formulating strategic policy positions across multiple therapeutic areas
- Support Bristol Myers Squibb engagement with pharmaceutical industry trade associations and various stakeholders on initiatives related to critical public policy issues, with a focus on patient access to innovative medicines
- Develop a comprehensive understanding of how public policy issues impact the biopharmaceutical industry, patients, caregivers, providers, and the broader healthcare delivery system

GLOBAL PATIENT OUTREACH

- Empower and embed patient experts and patient lived experience throughout BMS's drug discovery, development, and delivery process primarily through strategic partnerships focused on disease and therapeutic awareness and increasing access and health equity around the world
- Support advocacy initiatives that educate patients and providers to better understand treatment options and novel therapies for patients with serious diseases
- Partner and engage with priority US and global patient advocacy organizations to increase awareness of emerging science and inform BMS strategy
- Ensure the patient voice is elevated and central in all BMS patient advocacy initiatives and resources, to best support access to care and overcome key barriers

Non-Recruiting Fellowships

US ONCOLOGY MARKETING

Muhammad Usman, PharmD

Second-Year Fellow

St. John's University College of Pharmacy and Health Sciences

REGIONAL CLINICAL OPERATIONS

David Baker, PharmD

First-Year Fellow

Virginia Commonwealth University School of Pharmacy



COMMERCIAL BUSINESS INSIGHTS AND ANALYTICS

Sana Mansuri, PharmD

Second-Year Fellow

Rutgers University Ernest Mario School of Pharmacy

COMMERCIAL BUSINESS INSIGHTS AND ANALYTICS

Pranay Chinthaparthi, PharmD

First-Year Fellow

Rutgers University Ernest Mario School of Pharmacy

Leadership Spotlight

Melissa Harris, PharmD

Executive Sponsor
Senior Vice President, Regional Clinical Operations
Fellowship Year 2001-2002

Bristol Myers Squibb is a great company for pharmacists who are wanting to enter the pharmaceutical industry. The company recognizes the value of the unique skill set, training, and experience that enables pharmacists to excel and rise to important management and leadership roles. The diversity and cohesiveness of our PharmD program, and our associated pharmacy community at Bristol Myers Squibb, provides an exceptional experience of seeing, doing, and teaching, which readily prepares our Fellows/Residents to become future leaders within both our Medical and Commercial organizations. As leaders at Bristol Myers Squibb, we appreciate the importance of attracting and retaining these talented individuals to fulfill the Bristol Myers Squibb Company mission of helping patients prevail over serious diseases. The Rutgers PharmD Fellowship Program is clearly an important part of our talent acquisition strategy and is key to building and cultivating an innovative and diverse workforce at Bristol Myers Squibb.

Priya Darouian, PharmD

Steering Committee Lead
Senior Director, Customer Experience Strategy, Medical Engagement Excellence, MedEx
Fellowship Year 2003-2004

The Bristol Myers Squibb fellowship program has provided me with a solid foundation that prepared me for a successful career in the pharmaceutical industry. As a Fellow, I was an integral part of my team and was provided with a breadth of experiences. My preceptors and mentors were truly invested in my career growth and development. The experiences and friendships I have gained throughout my fellowship and current role are invaluable and will last me a lifetime. The program provides you with the necessary tools and opportunities you need to lead you on a path towards a rewarding career. I am proud to be a part of an organization that has a commitment and passion for patients.

Thomas Lehman, PharmD

Co-Steering Committee Lead
Executive Director, WW Medical Rheumatology
Fellowship Year 2012-2014

Selecting a fellowship at BMS was one of the best decisions I made to jump start my career during the fellowship interview and selection process. As a company with both a people and patient centric culture, a career at BMS for me has meant some of my proudest moments have had an impact for both patients and my career. Over a decade later I look back on my time and think about the people both in the fellowship community and beyond who have helped me succeed and contributed to my professional development. I can recommend no better place to both start and grow your career.

Bristol Myers Squibb Fellowship Alumni

Medical

Alejandro Nava Senior Manager, US Medical, Medical Excellence & Engagement Lead, GI & GU Portfolios
Anthony Salvatore Senior Director, US Medical, Oncology
Antonia Christodoulou Associate Director, Worldwide Medical, Rheumatology
Austin Bock Associate Director, Medical Communications, Cardiomyopathy
Caitlin Henley Senior Manager, Medical Scientist, US Medical Oncology, Gastrointestinal Cancers Portfolio
Carmelo Alonso Director, US Medical, Hematology Myeloid
Catherine Merrill Senior Director, Clinical Research Collaborations Lead, Oncology
Corey Rantz Associate Director, Medical Scientist, US Medical Oncology
Dorothy Zissler Associate Director, Worldwide Medical Affairs, Myeloid
Ijeoma Oyetunde Senior Director, Worldwide Medical Oncology
Jaime Bunn Director, Worldwide Medical Cardiovascular and Established Brands, Medical Communications
Jagruti Amin Associate Director, US Medical Promotional Review, Oncology
Joseph Kosto Associate Director, Franchise Medical Services
Josh Linton Director, US Medical Oncology, Targeted Therapies GI
Kaleen Barbary Director, Worldwide Medical Neuroscience, Medical Communications Neuropsychiatry
Keith Wittstock Director, Worldwide Medical Immunology & Neuroscience, Pulmonary Fibrosis
Max Prokopovich Director, Worldwide Medical Oncology, Thoracic Cancers
Nabomita Thomas Senior Director, WW Cell Therapy Portfolio Strategy
Patrick Liu Associate Director, US Myeloid Medical Excellence and Engagement Lead
Pavit Singh Senior Director, US Medical Affairs, Multiple Myeloma
Priya Darouian Senior Director, Medical Customer Experience (CX) Strategy
Ruchi Shah Senior Manager, Medical Scientist, US Medical Oncology
Samantha Pike Senior Manager, US Medical Oncology, Guidelines, Pathways, Formularies Strategy
Samantha Pomponi Director, Worldwide CV&I Medical, Rheumatology
Sonie Lama Executive Director, Cardiomyopathy, US Medical Lead
Stella Han Senior Medical Director, Worldwide Medical, Cardiovascular
Swara Kasbekar Associate Director, US Medical Oncology, Lung and Emerging Tumors Targeting Therapies
Thomas Lehman Executive Director, Global & US Medical Immunology & Autoimmunity
Trixia Camacho Vice President, MEG Oncology Head, Cross-Portfolio Excellence & MEG Alliances
Vincent Tran Associate Director, US Medical, Cell Therapy, PReP

Field Medical

Asia Ridley Medical Science Liaison, Oncology
Daniel Dilanji Regional Associate Director, US Field Medical Neurology
Gabriela Sikorska Senior Medical Science Liaison, Dermatology
Justin Balint Senior Director, Commercialization Strategy & Operations
Karan Verma Senior Medical Science Liaison, Neurology
Katherine Sprague Director, US Field Medical Portfolio Engagement Strategy, Cardiovascular
Khushbu Shah Associate Director, US Field Medical Strategy, Hematology
Kim Tran Vice President, US Field Medical, Hematology - Oncology
Lauren Marbury Executive Medical Science Liaison, Dermatology
Marie Labib Medical Science Liaison, Hematology
Raena Rhone Senior Medical Science Liaison, Neurology
Somtochukwu Egbuonu Medical Science Liaison, Neurology
Teena John Senior Medical Science Liaison, Neurology
Tia Belvin Medical Science Liaison, Cardiovascular
Zack Inge Executive Medical Science Liaison, Cardiovascular

BMS Foundation (Corporate Philanthropy)

Mason Chiang Associate Director, BMS Foundation
Ornesha Watson Associate Director, BMS Foundation

Commercial

Bernard Lee Director, US Commercialization Analytics, Immunology
Chloe Thomas Senior District Business Manager, Oncology
Christine Ghobrial Director, Global Commercial Strategy, Solid Tumor, GI
Christy Wong Senior Product Manager, US Marketing, Cell Therapy
Dylan Atkinson GU Marketing Lead, US Oncology
Evelyn Abramson Associate Director, US Marketing, GI Oncology
Frances Sousonis Associate Director, US Marketing, Cardiovascular HCP Marketing
Jade Hoang Director, US HCP Marketing, Eliquis
Jake Kinley Associate Director, US Marketing, Oncology
Lindsey Prima Director, Worldwide Commercial Strategy, Oncology
Nina Johnson Associate Director, US Marketing, Melanoma
Peter Fendt Director, BI&A
Spencer Heath Director, Customer Strategy, CAMZYOS

Market Access & Pricing

Amie Lette Senior Manager, Patient Access Marketing Hematology
Emily O'Neill Associate Director, Professional Marketing, Cardiovascular
Jennifer Liu Director, Global Commercial Strategy, Milvexian
Josh Dadural Senior Product Manager, Access Strategy, Oncology
Prianka Singh Director, Global Pricing and Access Strategic Lead

Regulatory Affairs

Alexander Cheung Associate Director, US Commercial Regulatory Affairs
Ashley Kelleher Global Regulatory Strategy Neurosciences
Christine Alonso Senior Director, US Commercial Regulatory Affairs, Oncology
Elsa Pan Senior Director, US Commercial Regulatory Affairs, Immunology/CV/Mature Brands
Jessica Zhu Senior Manager, Global Regulatory Strategy, Oncology
Kiri Roland Associate Director, Advertising and Promotion Commercial Regulatory Affairs, Oncology
Sekayi Mushonga Vice President, Global Regulatory Strategy, Immunology
Sohrab Sadeghi Senior Manager, Global Regulatory Strategy, Hematology
Trushna Shah Director, Regulatory Affairs, Immunology & Neuroscience
Yen Krystal Miao Associate Director, US Commercial Regulatory Affairs

Clinical

Amy Kim Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Andrew Mettias Senior Manager Clinical Scientist, Late Clinical Global Drug Development, Oncology
Brenda Yuan Associate Directo,r Senior Clinical Scientist, Cell Therapy
Brielle Carramusa Senior Manager, Clinical Scientist, Cardiovascular & Neuroscience
Corey Ritchings Clinical Development Lead, Oncology
Lana Mudarris Senior Manager, Clinical Scientist, Cardiovascular & Neuroscience
Maha Elgohail Senior Clinical Scientist, Cardiovascular
Melissa Harris Senior Vice President, Regional Clinical Operations
Nicholas Favatella Clinical Science Program Lead, Cardiovascular
Nishanth Viswanath Senior Manager, Clinical Scientist, Oncology
Sandhya Balachandar Clinical Science Lead, Immunology
Shannon Chandy Clinical Trial Lead, External Clinical Collaborations, Oncology
Victoria Berger Senior Clinical Scientist II, Immunology
Victoria MacLelland Clinical Scientist, Neuroscience
Will Jackson Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Yasmin Pirestani Clinical Scientist, Psychiatry

Business Development & Alliances

Matt Bunn Executive Director, Business Development and Licensing Transactions
Monica Anis Director, Business Development, Global Alliances

HEOR

Alexandra Kaiser Director, US Field HEOR

Policy & Advocacy

Aakash Patel Director, Policy Reimbursement and Quality
Chinenye Agim Senior Manager, Oncology Patient Advocacy
Shailee Gusani Associate Director, Executive Branch Strategy

ALUMNI

From Other RPIF Fellowship Companies

Medical

Alex Agyei Marfo (Pfizer) Associate Director, US Medical Affairs, Multiple Myeloma
Amber Griffies (Roche) Director, Worldwide Medical Oncology, Medical Communications
Hiba Malik (J&J) Associate Director, Worldwide/International Market Medical Learning, Oncology
Irfan Tejani (Sanofi) Senior Director, Worldwide Medical, Gastrointestinal Tumors
John Vaile (Bayer) Vice President, Global Program Lead, Immunology
Natanya Candelario (Roche) Senior Director, Global Health Equity
Omama Zubairi (Daiichi Sankyo) Associate Director, Medical Scientist, US Medical Oncology, GI
Ralu Vlad (Roche) Vice President, Head of Medical Evidence Generation
Sapna Patel (Novo Nordisk) Associate Director, Worldwide Medical Oncology, Medical Education
Shalon Jones (Dr. Reddy's Laboratories) Senior Director, WW Medical Affairs, Myeloid

Field Medical

Samantha Kaufman (J&J) Senior Medical Science Liaison, Oncology
Sheiva Khavari (Roche) Executive Medical Science Liaison, Rheumatology – Dermatology

Commercial

Akash Lall (Nevakar) Associate Director, Dermatology & Rheumatology HCP Marketing
Alberta Drake (Daiichi Sankyo) Associate Director, Worldwide Commercialization Analytics, Cell Therapy, Myeloma - Early Assets
Amanda Bright (Novartis) Associate Director, US HCP Marketing, Hematology
Brittany Rule (Bayer) Associate Director, Healthcare Professional - US Marketing, Neuroscience
Jessica Cairns (Roche) Vice President Cell Therapy Medical
Nora Khalil (J&J) Associate Director, Marketing – US Oncology

Market Access & Pricing

Joseph Lee (J&J) Director, Global Market Access, CV & Immunology
Lucy Eichenblatt (J&J) Global Market Access and Pricing Strategy Lead, Oncology
Parth Vashi (Bayer) Director, Global PASL Immunology and Neurosciences
Samaneh Kalirai (Eli Lilly) Senior Director, US Government Payers and Analytics

Regulatory Affairs

Andro Shenouda (Merck) Senior Director, Team Leader, Global Regulatory Sciences, Oncology
Angela Tang (Roche) Associate Director, Global Scientific and Regulatory Documentation
Charles Frost (Roche) Senior Director, Global Scientific and Regulatory Documentation
David Nguyen (J&J) Director, Global Regulatory and Safety Sciences Lead, Oncology
Jateh Major (Merck) Associate Director, Regulatory Affairs, Oncology
Jennifer Dudinak (Roche) Senior Vice President, Head of Global Regulatory Sciences
Kenneth Hu (Sanofi) Associate Director, Global Regulatory Sciences, Oncology
Mark Hanna (Merck) Associate Director, Intercontinental Regulatory Strategy Lead, Oncology
Matthew Wong (Daiichi-Sankyo) Executive Director, Global Regulatory Strategy, Hematology-Oncology
Nitin Kumar (Regeneron) Director, Global Regulatory Lead, Immunology
Omar Khalid (Allergan) Executive Director, Global Regulatory Strategy & Cross Therapeutic Area Excellence
Shih-Yi Kim (J&J) Executive Director, Global Regulatory Strategy, Immunology

Commercial Regulatory Affairs

Akshay Patel (Novartis) Associate Director, Commercial Regulatory Affairs
Jeff Sniggs (Acorda) Associate Director, Commercial Regulatory Affairs
Nicole Stoka (Novartis) Associate Director, US Commercial Regulatory Affairs

Global Business Operations

Kate Bender (Novartis) Senior Director, Investor Relations

Clinical

Bryan Campbell (Novartis) Senior Vice President, Head of Global Program Leaders, Hematology, Oncology, & Cell Therapy
Gabrielle Guancione (Merck) Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Geetha Pudussery (Novartis) Senior Clinical Scientist, Late Clinical Global Drug Development
Jennifer Han (Novartis) Clinical Scientist, Early Clinical Development, Hematology, Oncology, & Cell Therapy
Jennifer Poon (Merck) Director, Clinical Capabilities Lead, Clinical Center of Excellence
Jesse Siegel (Merck) Director, Clinical Collaboration Lead
Joseph Fiore (Merck) Vice President, Global Program Lead, Oncology
Julia Spiridigliozzi (Merck) Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Justin Dennie (Merck) Director, Clinical Science Lead, Oncology
Mackenzie Minogue (J&J) Associate Director, Senior Clinical Scientist, Late Clinical Development
Margee Kyada (Genentech) Associate Director, Senior Clinical Scientist, Clinical R&D Management
Marta Molina (Bimark) Executive Director, Global Program Lead, Eliquis
Michelle Hudson (Novartis) Vice President, Global Drug Development Strategic Operations
Naomey Sarkis (Novartis) Director, Early Clinical Development, Oncology
Ricky Philipossian (Pfizer) Associate Director, Clinical Scientist, Late Clinical Global Drug Development, Oncology
Ronak Patel (Pfizer) Director, Early Development Project Manager
Sapna Chhagan (Novartis) Executive Director, Early Clinical Development, Cell Therapy
Vani Vegesna (Pfizer) Associate Director, Senior Clinical Scientist, Late Clinical Global Drug Development, Oncology
Whitney Handy (Merck) Associate Director, Senior Clinical Scientist, Early Clinical Development

HEOR

Karishma Shelley (TJU/Novartis) Director, Worldwide Markets HEOR, Oncology
Laetitia N'Dri (TJU/Novartis) Associate Director, Worldwide Markets HEOR, Immunology
Miraj Patel (Sanofi) Director, Worldwide HEOR, Oncology

Policy & Advocacy

Brian Lee (Sanofi) Senior Director, Patient Advocacy, Corporate Affairs

***Not an Exhaustive List**
****Last Updated – August 2025**

Bristol Myers Squibb Component

The Fellows will become an integral part of their respective teams and will be trained to manage a broad range of responsibilities, similar to those managed by current team members. This fellowship program will necessitate interaction and teamwork with departments in all aspects of the corporation, such as Global Pharmacovigilance and Labeling, Sales, Medical Affairs, Marketing, Regulatory Services, Legal, Clinical Trials, Post-Marketing Clinical Research, and Health Care Channel Management. While at Bristol Myers Squibb, the Fellows will participate in various teambuilding activities and attend leadership development lectures with senior management. Key fellowship activities within Bristol Myers Squibb include:

MENTORSHIP PROGRAM

Participate in a mentorship program with senior management and fellowship alumni to discuss career development, networking, organization structure, market/industry knowledge, etc.

LUNCH AND LEARN SERIES

Attend lunch and learn series with executive sponsors and senior management to have interactive discussions.

BRISTOL MYERS SQUIBB FELLOWSHIP COMMITTEES

Lead and take part in the various fellowship committees such as: Co-Chief Fellows, Recruitment, Community Development, Professional Development, Alumni, and Scholarship committee.

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships

Soaring Ever Higher

Rutgers Pharmaceutical Industry Fellowship (RPIF) Program

Ernest Mario School of Pharmacy (EMSOP)

Rutgers, The State University of New Jersey

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor of EMSOP, Dr. Carolyn Seyss, the Executive Director for the Institute for Pharmaceutical Industry Fellowships, and Dr. Michael Toscani as the Director Emeritus.



Joseph A. Barone, PharmD, FCCP
Dean and Distinguished Professor



Carolyn Seyss, PharmD, RUCIF
Fellowship Executive Director

Michael Toscani, PharmD
Research Professor, Fellowship Director Emeritus

Program History

1984

EMSOP and 2 pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically- trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the RPIF Program grew significantly and expanded to now include 29 companies within the pharmaceutical and biopharmaceutical industry with over 300 Fellows.

2002

Dr. Ernest Mario generously provided an endowment to establish RPIF as an Institute to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Create the Fellowship structure, providing strategic leadership and administrative support
- Promote quality, communication, scholarly activity, and professional development
- Arrange specialized training opportunities within the pharmaceutical and biopharmaceutical industry

2018

RPIF expanded to offer interdisciplinary Fellows' training by adding physician Fellowship opportunities to our well-established program.

2023

The RPIF Certificate is recognized with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow).**

Well over 1,800 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.



Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the sponsor companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/ commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

Key Program Features

RPIF FOSTERs the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders.

Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Rutgers, The State University of New Jersey is one of the major state university systems in the United States. EMSOP is part of Rutgers Health and is the only state school of pharmacy in New Jersey. EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey.

While RPIF offers all the benefits of a large program with an extensive network of distinguished professionals, Fellows receive the individual attention of a small program where they are known and supported as individuals.

F

Family of Leading Companies
Partners include several top global pharmaceutical/biopharmaceutical companies and offer large to small company environments.

O

Outstanding Alumni Track Record
Well over 1,800 alumni hold prominent positions at many leading companies, including VP and C-suite levels.

S

Strong Network
Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.

T

Trusted and Proven Since 1984
The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry, developing foundations for future leaders

E

Enhanced Career Development
Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.

R

Rigorous Academic Component
Rutgers affiliation provides academic and professional development opportunities.

Application Process and Eligibility Requirements

Pharmacy Fellows for the RPIF Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy from an ACPE-accredited institution before July 1 of the fellowship term.

HOW TO APPLY:

The RPIF Program is highly competitive. **Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.**

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as **October 8, 2025** by visiting our website at: **https://pharmafellows.rutgers.edu/how-to-apply/**

All application materials must be submitted electronically to the RPIF website per instructions on the site.

REQUIRED ITEMS:	SUBMIT BY:
Application with short-answer questions	October 17th
Letter of Intent (LOI)	October 17th
Curriculum Vitae (CV)	October 17th
Letters of Recommendation (LORs)	December 1st

ADDRESS LOI AND LORs TO:

Joseph A. Barone, PharmD, FCCP
Dean and Distinguished Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships

"The RPIF Program hasn't just opened doors. It has changed the way I walk through them—more grounded in where I stand and more intentional in how I move forward. It has given me the opportunity to use my PharmD education to serve patients in new ways, shaping the conversations and decisions that impact their care. It has given me the confidence to speak up, the space to grow, and the kind of mentorship that sees your potential before you do. If you're ready to take the next step toward a career in the pharmaceutical industry, let RPIF be where your journey begins."

Pooja Singh, PharmD,
Global Regulatory Affairs and Global Value & Access Fellow
RPIF Chief Fellow

"Being a Rutgers Fellow has been such a pivotal part of my professional story, truly exceeding my expectations. This journey has transformed my leadership skills, giving me the confidence and tools I know I'll use every day. I'm grateful to be part of this community!"

Ginika Nwokeabia, PharmD
USMA/Medical Science Liaison - Neuroimmunology Fellow
RPIF Chief Fellow

"As a Rutgers Fellow, I have experienced an incredibly wide variety of opportunities through RPIF and my partner company. Through these opportunities I have learned and expanded my network more than I had ever imagined. The RPIF program encourages and facilitates all fellows growth into leaders and prepares us for our bright futures in the pharmaceutical industry."

Olivia Violette, PharmD
Global Medical Information Fellow
RPIF Chief Fellow

AIFA
Alliance of Industry Fellowship Associates

Aligned First Offer Date
December 12, 2025

The choice of a Post-Doctoral Industry Fellowship is an important decision. AIFA exists to promote a consensus first offer date for all Fellowship positions. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this AIFA-aligned offer date. Candidates should feel free to request an extension for any earlier offer to allow them to consider their options.

Connect with us on social media: @RutgersFellow

RUTGERS HEALTH
Institute for Pharmaceutical Industry Fellowships